NEWS
20487_FP_Header_Newsroom_Website_2400x900px

News

On this page find all the latest news, events and activities that involves Dr. Falk Pharma.

Corporate, Press release

Renexxion Ireland’s European Partner, Dr. Falk Pharma GmbH, has Elected PPI-nonresponsive SymptomaCc GERD as the Second Naronapride IndicaCon to Develop and Commercialize in their Licensed Territories

09.02.2024

ROSCREA, Ireland, and FREIBURG, Germany (GLOBE NEWSWIRE) [February, 7, 2024]– Renexxion Ireland Limited (“Renexxion”), a private biopharmaceuNcal…

More

Corporate, Press release

First patient treated in phase iib study of Naronapride in patients with gastroparesis

15.02.2023

Dr. Falk Pharma is committed to researching, developing, and launching innovative treatments for digestive and metabolic disorders. We do this both…

More

Corporate, Press release

Takeda Enters Collaboration and Licensing Agreement with Zedira and Dr. Falk Pharma to Develop First-in-Class Celiac Disease Therapy

20.10.2022

Collaboration Provides Takeda an Exclusive License to Develop and Commercialize ZED1227/TAK-227 in the United States and Other Countries Outside of…

More

Prometheus Logo
Corporate, Press release

Prometheus Biosciences and Dr. Falk Pharma Advance PR600 and Trigger Final Preclinical Milestone Payment

03.01.2022

SAN DIEGO, January 3, 2022 – Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology
company pioneering a precision medicine…

More

Logo Zedira
Corporate, Press release

Dr. Falk Pharma and Zedira announce start of the phase 2b real-life study of ZED1227 for the treatment of Celiac Disease

02.11.2021

Dr. Falk Pharma GmbH and Zedira announce start of the phase 2b clinical trial of ZED1227, a direct-acting and specific inhibitor of tissue…

More

Corporate, Press release

Renexxion Ireland Ltd. & Dr. Falk Pharma GmbH announce a Licensing and Collaboration Agreement

08.10.2021

Renexxion Ireland Ltd., a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need gastrointestinal…

More

Corporate, Press release

TGA regulatory approval for Jorveza 0.5mg orally disintegrating tablets

01.09.2021

Dr. Falk Pharma Australia is pleased to announce we have received TGA regulatory approval for Jorveza® 0.5mg orally disintegrating budesonide tablet -…

More

Corporate, Press release

Adults with EOE market research survey

02.02.2021

Dr. Falk Pharma would like to thank all responders to our survey on Adults with EoE.

More

Corporate, Press release

Dr. Falk Pharma Australia is pleased to announce the 2022 Dr. Falk Pharma-GESA research grant

02.02.2021

Dr. Falk Pharma Australia is pleased to announce the 2022 Dr. Falk Pharma-GESA research grant has been awarded to

More

Prometheus Logo
Corporate, Press release

Prometheus Biosciences and Dr. Falk Pharma GmbH Announce Global Collaboration Agreement to Develop and Commercialize a Novel IBD Antibody

13.08.2020

SAN DIEGO and FREIBURG, Germany, Aug. 13, 2020 /PRNewswire/ — Prometheus Biosciences, Inc., (“Prometheus”) a biopharmaceutical company committed to…

More